During ChinaTrials17, held at the JW Marriott Shanghai Tomorrow Square from November 12 (Wed) to 14 (Fri), 2025, the Japan Session “Clinical Development Opportunities in Japan” —planned and operated by Drug R&D Expert with support from Lychee Group, PharmaDJ, etc.— was successfully held on November 14 (Fri) (Main Program Day 2).  This was the only Japan-focused session at CT17.

Despite a packed agenda, this session secured the longest time slot at one hour.  With Ms. Mao Donglei, Editor-in-Chief, PharmaDJ serving as moderator, it featured a keynote address by Professor Kenichi Nakamura, Director, Department of International Clinical Development and Strategic Advisor to the Hospital Director at the National Cancer Center Hospital.  This was followed by a panel discussion where Mr. Tomohiro Nakamura (Director, Clinical Operations Japan, Global Development Organization, Takeda), Mr. Fumiaki Hamano (Head of Clinical Operations Japan, Global Clinical Operations, BeOne Medicines), Dr. Takaaki Tai (Quality Unit Director, Japan, Catalent), and Tetsuomi Takano (CEO & President, t2T Healthcare Inc.; Editor-in-Chief, Drug R&D Expert) also participated.

This year’s CT17, part of the 17-year history of ChinaTrials, featured a record-high six Japanese speakers.  Total attendance also reached a new high of over 800 participants, including the newly introduced Pitch Session, with lively discussions taking place across all sessions.